AdvisorShares Psychedelic... (PSIL)
AMEX: PSIL
· Real-Time Price · USD
18.00
0.11 (0.60%)
At close: Sep 11, 2025, 3:09 PM
17.60
-2.22%
After-hours: Sep 11, 2025, 05:41 PM EDT
0.60% (1D)
| Bid | 17.91 |
| Market Cap | 13.87M |
| AUM | 15.03M |
| NAV | 18.11 |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Shares Out | 755.18K |
| Inception Date | Sep 15, 2021 |
| Ask | 18 |
| Volume | 8,755 |
| Open | 17.72 |
| Previous Close | 17.89 |
| Day's Range | 17.72 - 18.00 |
| 52-Week Range | 7.14 - 18.40 |
| Holdings | 25 |
| Expense Ratio | 2.95% |
About PSIL
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.
Asset Class Equity
Ticker Symbol PSIL
Inception Date Sep 15, 2021
Provider Advisorshares
Website Fund Home Page
Exchange AMEX
Top 10 Holdings 71.17% of assets
| Name | Symbol | Weight |
|---|---|---|
| Atai Life Sciences N... | ATAI | 15.04% |
| Neuphoria Therapeuti... | NEUP | 8.42% |
| Mind Medicine (mindm... | MNMD | 7.85% |
| Compass Pathways Plc | CMPS | 7.29% |
| Nrx Pharmaceuticals,... | NRXP | 6.95% |
| Vistagen Therapeutic... | VTGN | 5.37% |
| Alkermes Plc | ALKS | 5.32% |
| Cybin Inc. | CYBN | 5.01% |
| Gh Research PLC | GHRS | 4.99% |
| Neurocrine Bioscienc... | NBIX | 4.93% |
Dividends Dividend Yield 1.31%
| Ex-Dividend | Amount | Payment Date |
|---|---|---|
| Jun 23, 2025 | $0.0119 | Jun 27, 2025 |
| Mar 21, 2025 | $0.1634 | Mar 28, 2025 |
| Sep 23, 2024 | $0.1087 | Sep 30, 2024 |
| Sep 25, 2023 | $0.0336 | Sep 29, 2023 |
| Sep 26, 2022 | $0.5421 | Sep 30, 2022 |
